CD39 anticorps (Extracellular Loop)
Aperçu rapide pour CD39 anticorps (Extracellular Loop) (ABIN7884923)
Antigène
Voir toutes CD39 (ENTPD1) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
-
-
Épitope
- AA 398-411, Extracellular Loop
-
Fonction
- A Rabbit Polyclonal Antibody to CD39
-
Homologie
- 14 amino acid residues identical, rat - 11,Mouse - 12
-
Purification
- Affinity purified on immobilized antigen.
-
Immunogène
- (C)KTSYAGVKEKYLSE, corresponding to amino acid residues 398-411 of human CD39
-
Isotype
- IgG
-
-
-
-
Indications d'application
-
WB: 1:200-1:400
FC: 2.5 μg per reaction
ICC: The optimal concentration should be determined by the user
IHC: The optimal concentration should be determined by the user
IP: The optimal concentration should be determined by the user
-
Commentaires
-
Negative Control: (ABIN7235254)
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- 0.2 mL double distilled water (DDW)
-
Concentration
- 1 mg/mL
-
Buffer
- PBS pH 7.4
-
Agent conservateur
- Without preservative
-
Stock
- -20 °C
-
Stockage commentaire
- The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C
-
-
- CD39 (ENTPD1) (Ectonucleoside Triphosphate diphosphohydrolase 1 (ENTPD1))
-
Autre désignation
- Ectonucleoside triphosphate diphosphohydrolase 1
-
Sujet
-
Synonyms: Ectonucleoside triphosphate diphosphohydrolase 1, NTPDase 1, Ecto-ATP diphosphohydrolase 1, Ecto-ATPDase 1, Ecto-apyrase, Lymphoid cell activation antigen, ENTPD1
Description: Ectonucleoside triphosphate diphosphohydrolase 1 (NTPDase1, ENTPD1, or CD39) is an enzyme that catalyzes the phosphohydrolysis of extracellular adenosine triphosphate (eATP) and diphosphate (eADP), that are released following inflammatory stress and cell injury, to adenosine monophosphate (AMP). AMP is then used by the ecto-5'-nucleotidase CD73 to synthesize adenosine1.Hydrolysis of adenosine triphosphate and adenosine diphosphate, performed by CD39, suppresses the immune system and inhibits T-cell and Natural killer (NK) cell responses. This inhibition has a role in promoting Chronic lymphocytic leukemia (CLL) and hence it is proposed that blockade or inhibition of CD39 may be a target for new immune therapy for CLL2. CD39 activity is also related to the occurrence of calcific aortic valve disease (CAVD)3, and to various other types of immune responses4. In addition, CD39 plays a dominant role in the purinergic regulation of inflammation1.The transcription of CD39 is constitutive in microvascular endothelium and certain immune cells. The modulated expression of NTPDase1 has been closely associated with inflammatory cytokines, oxidative stress and hypoxia in vitro and in vivo5.Localization of CD39 within lipid rafts suggests that this ecto-enzyme may be involved in cell-cell contact and signaling6.CD39 is a part of the ectonucleoside triphosphate dyphosphohydrolases (eNTDPase) protein family which shares a unique structural feature: instead of being anchored in the membrane by a single transmembrane domain or lipid link like other ectoenzymes, these proteins contain two transmembrane domains, one at each end of the protein. The active site lies in the large extracellular region. In addition, all family members share a set of short sequences termed apyrase conserved regions (ACRs)7.
-
ID gène
- 953
-
UniProt
- P49961
Antigène
-